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Background. The prevalence of b2-microglobulin amyloidosis
(Ab2m) in patients on continuous ambulatory peritoneal dialysis
(CAPD) is unknown.
Methods. We prospectively obtained a median of 2 (range 1 to
4) joint samples from 26 CAPD patients aged 44 to 93 (median
73) years at post-mortem evaluation after 4.5 to 126 (median 27)
months solely on CAPD (N 5 19) or primarily on CAPD (that is,
# 10% and # 1 year of renal replacement therapy time on other
modalities; N 5 7). The diagnosis of Ab2m rested on Congo red
staining (typical birefringence) and positive immunostaining of
amyloid deposits by a monoclonal anti-b2m antibody.
Results. Ab2m was diagnosed in 8 of 26 patients (31%).
Prevalence ranged from 20% (2 of 10 patients) within # 24
months CAPD to 30% (3 of 10 patients) after 24 to 48 months and
50% (3 of 6 patients) after 49 to 126 months (P 5 0.11). The
prevalence of Ab2m was similar in patients without or with one or
more peritonitis episodes. No significant difference in prevalence
(P 5 0.118) was found between CAPD patients (81/26; 31%) and
hemodialysis patients (131/26; 50%) carefully matched for time
on dialysis and age at the onset of dialysis.
Conclusions. The prevalence of histological Ab2m reaches 31%
after a median duration of 27 months of CAPD. This prevalence
is not significantly different from that observed in a group of HD
patients matched for age and dialysis duration.
Symptomatic b2-microglobulin amyloidosis (Ab2m) has
been reported occasionally in patients treated solely by
continuous ambulatory peritoneal dialysis (CAPD) [1, 2].
Yet, its actual prevalence remains to be defined: clinical
evidence of Ab2m usually develops over a period of 10
years [3], a delay largely exceeding the average technical
survival of CAPD [4]. In the absence of precise information
on the prevalence of Ab2m in CAPD, it has not been
possible to ascertain whether peritoneal dialysis delays the
onset of Ab2m when compared with hemodialysis (HD).
We recently demonstrated in a prospective autopsy study
of patients on chronic HD that histological evidence pre-
ceded clinical manifestations of Ab2m by several years [5].
We take advantage of this new approach to define the
prevalence of Ab2m in CAPD patients and to compare it
with that observed in HD subjects.
In the present prospective study of 26 patients treated by
CAPD for a median of 27 months, Ab2m was detected in 8
patients (31%). This prevalence was much higher than
hitherto appreciated and did not differ significantly from
that observed in a group of HD patients matched for age
and duration of dialysis.
METHODS
CAPD patients
Inclusion criteria. All patients who died while on CAPD
in participating units were submitted to a post-mortem
examination (unless refused by families). Inclusion started
in September 1988 in the co-ordinating center and in July
1992 in the other centers. Samples obtained up to May 31,
1997 are included in this report. Patients who had been
treated for more than 10% and/or more than one year of
the time on renal replacement therapy by another modality
(HD, renal transplantation) were not included [5, 6]. One
patient was excluded because of inadequate joint samples.
Patient characteristics. A total of 26 patients (18 males)
were included. Their ages ranged from 36 to 91 (median
69) years at dialysis onset and from 44 to 93 (median 73)
years at death. Total dialysis duration ranged from 4.5 to
126 months (median 27). Nineteen patients had been on
CAPD only, while the 7 others had received an additional
0.5 to 8 months of HD (median 1).
The cause of end-stage renal failure was nephrosclerosis
(N 5 10), diabetic nephropathy (N 5 6), amyloidosis (N 5
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4), chronic glomerulonephritis (N 5 4), autosomal domi-
nant polycystic kidney disease (N 5 1), and unknown (N 5
1).
A median of 1 (range 0 to 8) peritonitis episode was
recorded per patient throughout follow-up.
One single patient had undergone carpal tunnel syn-
drome (CTS) surgery prior to the onset of CAPD.
Death had resulted from: heart failure (N 5 8), myocar-
dial infarction (N 5 3), sudden cardiac death (N 5 2),
cerebrovascular disease (N 5 2), pneumonia (N 5 2),
sepsis (N 5 2), bladder cancer (N 5 1), ovarian cancer (N
5 1), suicide (N 5 1), dementia (N 5 1), hypovolemic
shock (N 5 1), mesenteric ischemia (N 5 1), and cachexia
(N 5 1).
Joint samples
The pathologists of participating units were asked to
obtain at least one large (diameter . 2 cm) joint sample
from all CAPD patients submitted to post-mortem exami-
nation. Specimens, fixed in 10% buffered formalin, were
forwarded to the co-ordinating center. After decalcification
in 5% formic acid for one to two weeks, they were
embedded in paraffin, cut and stained by alkaline Congo
red and by the avidin-biotin peroxidase complex and a
monoclonal anti-b2m antibody (dilution 1/100; Dako,
Copenhagen, Denmark) [5]. A total of 59 joint samples was
obtained from the 26 CAPD patients (range 1 to 4, median
2/patient, mean 2.3 6 1.3 SD). They included sternoclavic-
ular joints (N 5 40), shoulders (N 5 17), hip (N 5 1), and
wrist (N 5 1).
To compare the prevalence of Ab2m in CAPD and HD
patients, each CAPD patient was matched for age at the
onset of dialysis and time on dialysis with a HD patient.
The matching was performed by one of us (CvY) who was
unaware of the presence or absence of Ab2m in the
individual CAPD and HD patients.
A total of 76 (range 1 to 8, median 2/patient, mean 2.9 6
1.7) joint samples was available in this control group.
Pathological diagnosis
All slides were reviewed by the same team of pathologists
(CG and HN) who were blinded to the clinical character-
istics of the patients. The diagnosis of amyloidosis rested on
a positive Congo red staining with characteristic green
yellow birefringence under polarized light. In all patients
with joint amyloidosis, at least one joint sample was stained
by the immunoperoxidase technique with the anti-b2m
antibody. Ab2m was diagnosed when the amyloid deposits
detected by Congo red reacted with the anti-b2m antibody
[5].
Statistical analysis
The prevalence of Ab2m in CAPD and HD patients was
compared by calculating an odds ratio (OR) for matched
studies. The significance was assessed using the Logit-
Woolf method.
P values , 0.05 were considered to be significant.
RESULTS
Histological prevalence of Ab2m in CAPD patients
Ab2m was diagnosed in 8 of 26 patients (31%), as early
as within 21 months CAPD. The prevalence ranged from
20% (2 of 10 patients) after 1 to 24 months to 30% (3 of 10
patients) after 25 to 48 months and 50% (3 of 6 patients)
after 49 to 126 months CAPD (P 5 0.11, Armitage test for
increasing trend in prevalences)
Inclusion of the few months of HD treatment did not
modify these results.
Histological Ab2m and previous CTS surgery
The single patient who underwent CTS surgery had no
b2m amyloid deposits in the tissue removed during CTS
surgery or in the joints after 25 months CAPD.
Histological Ab2m and amyloidosis as a cause of end-
stage renal failure
Renal amyloidosis was the cause of ESRD in four
patients who dialyzed respectively for 8, 25, 29 and 126
months. Evidence of Ab2m was present only in the latter
patient.
Histological Ab2m and number of peritonitis episodes
The prevalence of Ab2m was similar in patients without
an episode (3 of 9, 33%), with one episode (3 of 7, 43%) or
more than one episode (2 of 10, 20%).
Comparison of Ab2m prevalence in CAPD and HD
patients
As shown in Table 1, age and time on dialysis were not
different in CAPD patients and in matched HD patients.
The prevalence of Ab2m was not significantly different
between the two groups: 31% (8 of 26) and 50% (13 of 26)
in CAPD and HD patients, respectively (OR 3.5; 95% CI
0.73 and 16.7; P 5 0.118).
No significant difference was found even between sub-
groups of CAPD and HD patients with a similar dialysis
duration (Table 2).
DISCUSSION
Our data quantify for the first time, to our knowledge,
the prevalence of Ab2m in patients treated exclusively or
Table 1. Age at dialysis onset and time on dialysis of CAPD patients
and matched HD patients
CAPD patients HD patients P value
Age at dialysis onset years 68.6 6 11.2 67.3 6 9.4 0.66
Time on dialysis months 38.5 6 31.3 40.7 6 32 0.80
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almost exclusively by CAPD. Surprisingly, the prevalence
of Ab2m had already reached 20% within the first two years
of therapy. The overall prevalence in patients followed for
4.5 to 126 months on CAPD reached 31%. The 50%
prevalence of Ab2m observed in the 49 to 156 month group
suggests that improvements in the technical survival of
CAPD will be accompanied by a rising incidence of symp-
tomatic Ab2m.
These results may be taken as representative of the
prevalence of joint Ab2m. Indeed, at least one sternocla-
vicular joint sample, reputed for its sensitivity (97%) in the
detection of joint Ab2m [5], was obtained from all CAPD
patients in whom no Ab2m was detected, except one. Just
as in HD [5], histological evidence precedes the clinical
symptoms of Ab2m by several years.
Until now, the actual prevalence of Ab2m in patients on
CAPD could not be calculated. Indeed, the clinical mani-
festations used to assess Ab2m (CTS and bone cysts)
develop late after the onset of renal replacement therapy
[3]. The short technical survival of CAPD [4] therefore
precludes a precise assessment of the prevalence of Ab2m.
The present results permit to compare the prevalence of
Ab2m in patients treated by CAPD and HD. The compar-
ison is reliable. Indeed, the same method was used to detect
Ab2m in joints obtained at autopsy during the same time
interval. Furthermore, in this study the CAPD and HD
patients were carefully matched for age at the onset of
dialysis and time on dialysis, two major risk factors for
Ab2m [5, 6].
Although prevalence is identical in the two groups within
the first years of dialysis, it tends to be lower subsequently
in the CAPD population, without reaching statistical sig-
nificance. Overall, for the same duration of treatment,
prevalence reached 31% in the CAPD versus 50% in the
HD group. The lack of statistical significance of this
difference might be related to the limited size of the
population, that is, a b-type statistical error. It may be
calculated that the sample size should increase to over 50
patients in each group for statistical significance to be
reached. At any rate the present data suggest that the
actual difference should not exceed 20%.
Patients on CAPD were expected to have a lower
prevalence of Ab2m than those on HD as a result of their
lower serum b2m levels [7, 8]. Of note, the only study
claiming that serum b2m levels were similar in CAPD and
HD patients failed to match them for residual renal
function (or diuresis) [9], which is a major determinant of
the serum b2m level [10].
Two clinical studies have compared the prevalence of
clinical manifestations of Ab2m in CAPD and HD patients
[11, 12]. Each study had shortcomings and the conclusions
were contradictory. Nomoto et al reported a very low
prevalence of CTS (0.14%) in a population of 5050 CAPD
patients [11]. However, they failed to compare these results
with an appropriately matched group of HD patients. In
addition, the likelihood of CTS being due to Ab2m is
limited by the fact that Ab2m was demonstrated in only one
of the seven CTS cases, all of whom were females known to
be at high risk of CTS in the absence of uremia [13].
Detailed evaluation of these results is further hampered as
neither mean age, mean duration on CAPD, nor the time
possibly spent on HD were provided in this paper [11].
Benz, Siegfried and Teehan concluded that there was no
difference in the prevalence of CTS, evaluated by nerve
conduction studies, between 90 HD and 61 CAPD treated
patients: 18% and 14% of the patients had nerve conduc-
tion abnormalities after a mean follow-up of 51.6 and 33.8
months on HD and CAPD, respectively [12]. However, the
average age of both groups at the onset of dialysis was not
mentioned.
Schwalbe et al recently reported a profound drop in the
prevalence of Ab2m in their HD patients between 1988 and
1996 [14]. They speculated that this fall reflected recent
improvements in dialysate purity and their attendant reduc-
tion in infraclinical inflammatory stimuli [14]. In our study,
despite the use of sterile pyrogen-free peritoneal dialysate,
Ab2m affected nearly one third of patients on dialysis for a
median of 27 months only. This suggests that dialysate
purity is not a major determinant of Ab2m prevalence and
that alternative explanations should be considered for
Schwalbe et al’s observations. The lack of an association
between the number of peritonitis episodes and Ab2m
prevalence in our CAPD cohort fits with this suggestion. It
should be noted, however, that peritoneal dialysis may be
associated with systemic monocyte activation [15] that may
contribute to Ab2m genesis even in peritonitis-free pa-
tients.
In conclusion, the histological prevalence of joint Ab2m
reaches 31% (8 of 26) after a median of 27 months CAPD,
a much higher number than hitherto appreciated. It is not
significantly different from that observed in a group of HD
patients matched for age and time on dialysis.
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